Selektierte Bibliographie zu den halluzinogenen Tryptaminen

  1. Amold O. H., Hofmann G.: "Zur Psychopathologie des Dimethyltryptaminein weiterer Beitrag Zur Pharmakopsychiatrie,", Wien. Zeitschr. Nervenh., Bd. 13, S. 438-445, 1957.
  2. Axelrod T.: "Enzymatic formation of psychotomimetic metabolites from normally occurring compounds", Science, Bd. 134, S. 343, 1961.
  3. Axelrod T.: "The enzymatic N-methylation of serotonin and other amines", J. Clin. Endrocrinol. Metab., Bd. 61, S. 388-390, 1962.
  4. Barker S.A., Monti T.A., Christian S.T.: "N,N- Dimethyltryptamine: an Endogenous Hallucinogen", International Review of Neurobiology, Bd. 22, S. 83-110, 1981.
  5. Beaten J., Morris P.: "Ontogeny of N,N- dimethyltryptamine and related indolealkylamine levels in neonatal rats", Mech. Age. Develop., Bd. 25, S. 343-347.
  6. Benington F., Morin R.D, Clark L.C.: "5-Methoxy- N,N-dimethyltryptamine, a possible endogenous psychotoxin", Ala. J. Med. Sci., Bd. 2, S. 397-403, 1965.
  7. Bickel P., Dittrich A., Schoepf J.: "Feine experimentelle Untersuchung zur bewusstseinveraendenden Wirkung von N,N-Dimethyl-tryptamine (DMT)", Pharmakopsychiatr. Neuropsychopharmakol., Bd. 9, S. 220- 225, 1976.
  8. Borsey J., Lenard K., Csizmadia Zs.: "Uber die zentrale Wirkung von Diathyltryptamin und seiner an 2. Stelle substituierten aromatischen Derivative im Zusammenhang mit den Mediatorsubstanzen der autonomen Zentren", Acta Physiol. Acad. Sci. Hung., Bd. 18, S. 83-84, 1961.
  9. Boszormenyi Z., Der P., Nagy T.: "Observations on the psychotogenic effect of N,N-diethyltryptamine, a new tryptamine derivative", J. Ment. Sci., Bd. 105, S. 171-181, 1959.
  10. Boszormenyi A, Szara S: "Dimethyltryptamine experiments with psychotics", J Mental Sci, Bd. 104, S. 445-453, 1958.
  11. Bradley P.B., Deniker P., Radouco-Thomas C. (Hg.): "Neuropsychopharmacology", Elsevier, 1959.
  12. Bradley P.B., Fliigel F., Hoch P.H. (Hg.): "Neuropharmacology, Vol. III, Proceedings of the Third Meeting of the Collegium Internationale Neuro-Psychopharmacologicum", Elsevier, 1964.
  13. Brimblecombe, Finder: "Hallucinogenic Agents".
  14. Brune G.B., Pscheidt G.R.: "Correlations between behavior and urinary excretion of indole amines and catecholamines in schizophrenic patients as affected by drugs", Federation Proc., Bd. 20, Nr. 4, Dezember, S. 889-893, 1961.
  15. Burroughs W.S., Ginsberg A.: "The Yage Letters", City Lights Books, 1988.
  16. Cerletti A., Taeschler M., Weidmann H.: "Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines", Adv. Pharmacol. Chemother., Bd. 6B, S. 233-246, 1968.
  17. Christian S.T. et al.: "The in vitro Identification of Dimethyltryptamine (DMT) in Mammalian Brain and its Characterization as a Possible Endogenous Neuroregulatory Agent", Biochemical Medicine, Bd. 18, S. 164-183, 1977.
  18. Corbett L. et al.: British Journal of Psychiatry, Bd. 132, S. 139-144, 1978.
  19. Cole JM, Pieper WA: "The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys", Psychopharmacologia, Bd. 29, S. 107-112, 1973.
  20. Cottrell A., McLeod M., McLeod W.: "A bufotenin- like substance in the urine of schizophrenics", Am. J. Psychiatry, 134, S. 322-323.
  21. DeMontigny C., Aghajanian G.: "Preferential action of 5methoxy-tryptamine and 5-methoxy-dimethyl- tryptamine on presynaptic serotonin receptors: A comparative iontophoretic study with LSD and serotonin", Neuropharmacology, Bd. 77, S. 811-818, 1977.
  22. Der Marderosian A, Pinkley HV, Dobbins MF: "Native Use and Occurrence of N,N-Dimethyltryptamine in the Leaves of Banisteriopsis Rusbyana", Lloydia, 1968, Bd. 31, S. 430.
  23. Evans-Wentz W.Y.: "The Fairy Faith in Celtic Countries (introduction by T. McKenna)", Citadel Press, 1990.
  24. Fabing H.D.: "On going berserk: a neurochemical inquiry", Am. J. Psyclzint., Bd. 113, S. 409-415, 1956.
  25. Fabing H.D., Hawkins J.R.: "Intravenous bufotenine injection in the human being", Science, Bd. 123, S. 885-887, 1956.
  26. Fabing H.D. et al.: "Bufotenine effects in humans", Fed. Proc., Bd. 15, S. 421, 1956.
  27. Fish M.S., Johnson N.M., Horning E.C.: J. Am. Chem. Sec., Bd. 77, S. 5892, 1955.
  28. Fish M.S., Horning E.C.: "Studies on Hallucinogenic Snuffs", J. Nerv. & Ment. Dis., Bd. 124, S. 33-37, 1956.
  29. Fisher G.: "Some Comments Concerning Dosage Levels of Psychedelic Compounds for Psychotherapeutic Experiences", Psychedelic Review, Bd. 2, S. 208-218, Herbst, 1963.
  30. Flammarion C.: "Mysterious Psychic Forces", Boston, 1907.
  31. Freedman D.X.: "Aspects of the Biochemical Pharmacology of Psychotropic Drugs,", Psychedelic Review, Bd. 8, S. 33-58, 1966. Reprinted from Solomon P.: (Hg.): "Psychiatric Drugs", Grune & Stratton, 1966.
  32. Garattini S., Ghetti V. (Hg.): "Psychotropic Drugs", Elsevier, 1957.
  33. Gessner P.K., McIsaac W.M., Page I.H.: "Pharmacological actions of some methoxyindole- alkylamines", Nature, Bd. 190, S. 179-180, 1961.
  34. Gessner P.K. et al.: "The relation between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin", J. Pharmacol. Exp. Therp., Bd. 130, S. 126-133, 1960.
  35. Gessner P.K., Page I.H.: "Behavioral effects of 5-methoxy- N,N-dimethyltryptamine, other tryptamines, LSD,", Am. J. Physiol., Bd. 203, S. 167-172, 1962.
  36. Gessner P.K., Dankova J.: "Brain bufotenine from administered acetylbufotenine: Comparison of its tremorigenic activity with that of N,N-dimethyltryptamine and 5-methoxy- N,N-dimethyltryptamine", Pharmacologist, Bd. 17, S. 259, 1975.
  37. Giarman N.J.: "Discussion of Kety [61]", Federation Proc., Bd. 20, Nr. 4, S. 897-900, Dezember, 1961.
  38. Gillin J., Kaplan, Stillman, Wyatt: "The psychedelic model of schizophrenia: The case of N,N-dimethyltryptamine", Am. J. Psychiatry, Bd. 133, Nr. 2, S. 203-208, 1976.
  39. Gillin J., Stoff D.M., Wyatt R.J.: "Transmethylation hypothesis: A review of progress,", In: Lipton M.A., DiMascio A., Killam K.F. (Hg.): "Psychopharmacology: A Generation of Progress", Raven Press, S. 1097-1112, 1978.
  40. Gillin J. et al.: "5-methoxy-N,N-dimethyltryptamine: Behavioral and toxicological effects in animals", Biol. Psychiatry, Bd. 11, S. 355-358, 1976.
  41. Gillin JC, Cannon E, Magyar R et al: "Failure of N,N- dimethyltryptamine to evoke tolerance in cats", Biol Psychiatry, Bd. 7, S. 213-220, 1973.
  42. Glennon R.A., Liebowitz S.M., Mack E.C.: "Serotonin receptor binding affinities of several hallucinogenic phenylalkylamine and N,N-dimethyltryptamine analogues", J. Med. Chem., Bd. 21, S. 822-825, 1978.
  43. Glennon R.A. et al.: "Bufotenine esters", J. Med. Chem., Bd. 22, S. 1414-1416, 1979.
  44. Glennon R.A., Young R., Jacyno J.A.: "Indolealkylamine and phenylalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioural activity", Biochem. Pharmac., Bd. 32, S. 1267-1273, 1983.
  45. Glennon R.A., Titeler M., McKenneY J.: "Evidence for 5HT2 involvement in the mechanism of action of hallucinogenic agents", Life Sci., Bd. 35, S. 2505-2511, 1984.
  46. Gracie & Zarkov: "Notes from Underground", privately printed, 1985.
  47. Granier-Doyeux M.: "Una Toxicomania Indigena: El Uso de la Piptadenia peregrinn", Revista Tecnica, Bd. 2, S. 49-55, 1956.
  48. Gucchait R: "Biogenesis of 5-methoxy-N,N- dimethyltryptamine in human pineal gland", J. Neurochem., Bd. 26, S. 187-190, 1976.
  49. Guenter G.B., Pscheidt G.R.: "Correlations between behavior and urinary excretion of indole amines and catecholamines in schizophrenic patients as affected by drugs", Feder. Proc., Bd. 20, S. 889-893, 1961.
  50. Harner M. (ed.): "Hallucinogens and Shamanism", Oxford University Press, 1973.
  51. Hartley R., Smith J.: "The activation of pineal hydroxy-indole-O-methy1 transferase by psychotomimetic drugs", J. Pharm. Pharmacol., Bd. 25, S. 751-752, 1973.
  52. Heinze W. et al.: "The acute and chronic effect of 5-methoxy-tryptamine on selected members of a primate social colony", Biol. Psychiatry, Bd. 15, S. 829-838, 1980.
  53. Hess S.M., Redfield B.G., Udenfriend S.: "The effect of monoamine oxidase inhibitors and tryptophan on the tryptamine content of animal tissues and urine", J. Pharmacol. Exp. Ther., Bd. 127, S. 178-181, 1959.
  54. Himwich H.E., Kety S.S., Smythies J.R. (Hg.): "Amines and Schizophrenia", Pergamon Press, 1967.
  55. Himwich H.E.: "Introductory Remarks" to symposium, 'Effects of Hallucinogenic Drugs in Man'", Federation Proc., Bd. 20, Nr. 4, S. 874-875, Dezember, 1961.
  56. Hofmann A. et al.: Experientia, Bd. 14, S. 107, 1958.
  57. Holmstedt B.: "Tryptamine derivatives in Epena, an intoxicating snuff used by some South American Indians", Arch. Int. Pharmacodyn. Ther., Bd. 156, S. 285-305, 1965.
  58. Horowitz M., Palmer C.: "Shaman Woman /Mainline Lady: Women's Writings on the Drug Experience."
  59. Jacobs B.L. (ed.): "Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives", Raven Press, New York, 1984.
  60. Jacob MS, Presti DE.: "Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine", Med Hypotheses, Bd. 64, Nr. 5, S. 930-7, 2005.
  61. Janiger Oscar: "verbal communication", Februar, 1991.
  62. Kaplan J, Mandel LR, Stillman R et al: "Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive doses to human subjects", Psychopharmacologia, Bd. 38, S. 239-245, 1956
  63. Karkkainen T. et al.: "Urinary excretion of free bufotenin by psychiatric patients", Biol. Psychiatry, Bd. 24, S. 441-446, 1988.
  64. Kensinger K.M.: "Banisteriopsis Usage Among the Peruvian Cashinahua", In: Harner M. (Hg.): "Hallucinogens and Shamanism", Oxford University Press, S. 9-14, 1973.
  65. Kety S.S.: "Possible relation of central amines to behavior in schizophrenic patients", Federation Proc., Bd. 20, Nr. 4, S. 894-896, Dezember, 1961.
  66. Koella WP, Beaulieu RF, Bergen JR: "Stereotyped behavior and cyclic changes in response produced by LSD in goats", Int J Neuropharmacol, Bd. 3, S. 398-403, 1964.
  67. Kovacic B, Domio EF: "Tolerance to behavioral effects of dimethyltryptamine (DMT) in the rat (abstract)", Fed Proc, Bd. 33, S. 549, 1974.
  68. Kusel H.: "Ayahuasca Drinkers among the Chama Indians of North-East Peru", Psychedelic Review, Bd. 6, S. 58-66, 1965.
  69. Leary, T.: "Programmed Communications during Experiences with DMT (Dimethyltryptamine)", Psychedelic Review, Bd. 8, S. 83-95, 1966.
  70. Lipton M.A., DiMascio A., Killam K.F. (Hg.): "Psychopharmacology: A Generation of Progress", Raven Press, 1978.
  71. Mandel L., Walker R.: "The biosynthesis of 5-methoxy-N,N-dimethyl-tryptamine in vitro", Life Sci., Bd. 15, S. 1457-1463, 1971.
  72. McKenna D.J., Towers G.H.: "Biochemistry and pharmacology of tryptamines and beta-carbolines: A mini review", J. Psychoactive Drugs, Bd. 16, Nr. 4, Okt-Dez, S. 347-358, 1984.
  73. McKenna D. et al.: "Differential Interactions of Indolealkylamines with 5-Hydroxytryptamine Receptor Subtypes", Neuropharmacology, Bd. 29, S. 193-198, 1990.
  74. McKenna DJ, Towers GH, Abbott F.: "Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.", J Ethnopharmacol., April, Bd. 10, Nr. 2, S. 195-223, 1984.
  75. McKenna D., McKenna T.: "The Invisible Landscape", Seabury Press, 1975.
  76. McKenna T.: "Among Ayahuasquera", In: Raetsch C. (Hg.): "Gateway to Inner Space", Prism Press, S. 179-211, 1989.
  77. McKenna T.: "Wahre Halluzinationen", Gaia Media AG, 1991.
  78. McKenna T.: "True Hallucinations", 8 tapes, Lux Natural.
  79. McKenna T.: "Tryptamine Hallucinogens and Consciousness", tape, Lux Natural.
  80. McKenna T.: "Psilocybin and the Sands of Time", tape, Lux Natural.
  81. McKenna T., Abraham R.: "New Maps of Hyperspace", tape, Lux Natural.
  82. McLeod W.R., Sitaram B.R.: "Bufotenine reconsidered", Acta psychiatr. scan., Bd. 72, S. 447-450, 1985.
  83. Merlin M.D., Allen J.W.: "Species identification and chemical analysis of psychoactive fungi in the Hawaiian islands", Journal of Ethnopharmacology, Bd. 40, Nr. 1, S. 21-40, 1993.
  84. Metzner R.: "The Pharmacology of Psychedelic Drugs", Psychedelic Review, Bd. 1, S. 69-115, 1963.
  85. Metzner R.: "Hallucinogens in Contemporary North American Shamanic Practice. Proceedings of the Fourth International conference of the Study of Shamanism and Alternate Modes of Healing", S. 171-175, 1987.
  86. Miller Jr. O.K.: "Mushrooms of North America", Dutton & Co., Springfield, 1972.
  87. Misztal S.: "Synteza N,N-dwumetylod-hydroksytryptaminy I N-Metylo-5-metoksytryptaminy", Diss. Phamznceut., Bd. 11, S. 11-15, 1959.
  88. Most Albert: "Bufo Alvarius: the Psychedelic Toad of the Sonoran Desert", Venom Press Box 2863, Denton TX 76202, 1984.
  89. Most Albert: "Eros and the Pineal: the layman's guide to cerebral solitaire", Venom Press, Denton, TX, 1986.
  90. Murphree H.B. et al.: "Effects in Normal Man of a-methyltryptamine and a-ethyltryptamine", Clin. Phnrmacol. Therapeut., Bd. 2, S. 722-726, 1961.
  91. Naranjo C.: "Psychotherapeutic possibilities of new fantasy-enhancing drugs", Clin. Toxycol., Bd. 2, S. 209-224, 1969.
  92. Naranjo C.: "Psychotropic Properties of the Harmala Alkaloids", In: Efron (Hg.): "The Ethnopharmacologic Search for Psychoactive Drugs", 1969.
  93. Nichols David E., Glennon Richard A: "Medicinal Chemistry and Structure-Activity Relationships of Hallucinogens", In: Jacobs B.L. (Hg.): "Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives", Raven Press, New York, S. 95-142, 1984.
  94. Nichols David E.: "Studies of the relationship between molecular structure and hallucinogenic activity", Pharmac. Biochem. Behav., Bd. 24, S. 335-340, 1986.
  95. Pachter I.J, Zacharias D.E, Ribeir O.: "Indole Alkaloids of Acer saccharinum (the Silever Maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis.", J Org Chem, Bd. 24, S. 1285-7, 1959.
  96. Pfeifer A.K., SBtory E., Pataky I., Vizy E.: "Einfluss der Tranquillantien auf die Wirkung von Diaethyltryptmin (DET)", Acta Physiol. Acad. Sci. Hung., Bd. 18, S. 82-83, 1961.
  97. Phillips R.: "Mushrooms and other fungi of Great Britain and Europe", Pan Books, London, 1981.
  98. Poupat C., Ahond A., Sevenet T.: "Alcaloides De Acaia simplicifolia", Phytochemistry, Bd. 15, S. 2019-2120, 1976.
  99. Raetsch C. (ed.): "Gateway to Inner Space", Prism Press, 1989.
  100. Repke D.B., Grotjahn D.B., Shulgin A.T.: "Psychotomimetic N-methyl-N-isopropyl-tryptamines. Effects of variation of aromatic oxygen substituents", J. Med. Chem., Bd. 28, S. 892-896.
  101. Richards W.A. et al: "The peak experience variable in DPT-assisted psychotherapy with cancer patients", J. Psychedelic Drugs, Bd. 9, S. 1-10, 1977.
  102. Richman G. D.: "The Santo Daime Doctrine: An Interview with Alex Polari De Alverga", Shaman's Drum, Bd. 22, S. 30-41, Winter, 1990-1.
  103. Rivier L., Lindgren J.-E.: "'Ayahuasca', the South American Hallucinogenic Drink: an Ethnobotanical and Chemical Investigation", Economic Botany, Bd. 26, S. 101-129, 1972.
  104. Rivier L., Pilet P.E.: "", Annee Biologique, Bd. 10, S. 129, 1971.
  105. Rosenberg D.E., Isbell H., Miner E.T.: "Comparison of a placebo, N-dimethyltryptamine and 6-hydroxy-N- dimethyltryptamine in man", Psychopharmacologia, Bd. 4, S. 39-42, 1963.
  106. Robbers J.E., Tyler V.E., Ola'h G.M.: "Additional evidence supporting the occurrence of psilocybin in Panaeolus foenisecii", Lloydia, Bd. 32, S. 399-400, 1969.
  107. Rovelli B., Vaughan G.N.: "Alkaloids of Acacia I. Dimethyltryptamine in Acacia phlebophylla.", Aust. J Chem., Bd. 20, S. 1299-1300, 1967.
  108. Saavedra J., Axelrod T.: "Psychotomimetic N-methylated tryptamines: Formation in brain in vive and in vitro", Science, 175, S. 1365-1366.
  109. Sai-Halasz A., Brunecker G., Szara S.: Psych. Neurol., Bd. 135, S. 285, 1958.
  110. Sai-Halasz A., Brunecker G., Szara S.: "Comnzun.", Bd. 1, S. 93-98, 1975.
  111. Saupe S.G.: "Occurence of Psilocybin/Psilocin in Pluteus salicinus (Pluteaceae)", Mycologia, Bd. 73, S. 781-784, 1981.
  112. Shulgin A.T.: "Psychotomimetic agents", In: Gordon M. (Hg.): "Psychopharmacological Agents, Vol IV", New York, Academic Press, 1976.
  113. Shulgin A.T.: "Chemistry of Psychotomimetics", In: Hoffmeister F., Stille G. (Hg.): "Handbook of Experimental Pharmacology, Bd. 55: Alcohol and Psychotomimetics, Psychotropic Effects of Central-Acting Drugs", New York, Springer-Verlag, 1982.
  114. Siegel R.K., Jarvik M.E.: "DMT self-administration by monkeys in isolation", Bull. Psychonomic Sec., Bd. 16, S. 117-120, 1980.
  115. Siegel R.K.: "Intoxication", Simon & Schuster, 1989.
  116. Skaltsounis A.L., Tillequin F., Koch M.: "Plantes des Nouvelle- Caledonie LXXXIII: Alcaloides des tiges feuillees de Melicope leptococca", Lloydia B , Bd. 46, Nr. 5, S. 732, 1983.
  117. Smith, T.A.: "Review: Tryptamine and Related Compounds in Plants", Phytochemistry, Bd. 16, S. 171-175, 1977.
  118. Smythies J.R., Bradley R.J., Johnson V.S.: "The behavioral effects of some derivatives of mescaline and N,N- dimethyltryptamine in the rat", Life Sci., Bd. 6, S. 1887- 1893, 1967.
  119. Smythies J.R., Morin R.D., Brown G.D.: "Identification of dimethyltryptamine and O-methylbufotenine in human cerebrospinal fluid by combined gas chromatography/mass spectrometry", Biol. Psychiat., Bd. 14, S. 549-556, 1979.
  120. Solomon P. (ed.): "Psychiatric Drugs", Grune & Stratton, 1966.
  121. Soskin R.A.: "Dipropyltryptamine in psychotherapy", Curr. Psychiafr. Theu., Bd. 15, S. 147-156, 1975.
  122. Soskin R.A., Grof S., Richards W.A.: "Low doses of dipropyltryptamine in psychotherapy", Arch. Gen. Psychiatry, Bd. 28, S. 817-822, 1973.
  123. Stein S.I.: "Clinical Observations on the Effects of Panaeolus venenosus Versus Psilocybe caerulescens Mushrooms", Mycologica, Bd. 51, S. 49, 1959.
  124. Stijve T., Klan J., Kuyper W.: "Occurrence of psilocybin and baeocystin in the genus Inocybe", Persoonia, Bd. 12, S. 469-472, 1985.
  125. Stijve T., De Meijer A.A.R.: "Macromycetes from the state of Parana, Brazil. 4. The psychoactive species", Arquivos de Biologia e Tecnologia (Curitiba), Bd. 36, Nr. 2, S. 313-329, 1993.
  126. Stillman R.C., Willette R.E. (Hg.): "The Psychopharmacology of Hallucinogens", Pergamon, 1978.
  127. Strassman R.: "The Pineal Gland: Current Evidence for its Role in Consciousness", In: Lyttle, T. (Hg.): "Psychedelic Monographs and Essays", Bd. 5, S. 167-205, 1990-1991.
  128. Strassman R.: "correspondence", 1990-91.
  129. Strassman RJ.: "Human psychopharmacology of N,N-dimethyltryptamine", Behav Brain Res., Bd. 73, Nr. 1-2, S. 121-4, Dec 1996. Abstract: "We generated dose-response data for the endogenous and ultra-short-acting hallucinogen, N,N-dimethyltryptamine (DMT), in a cohort of experienced hallucinogen users, measuring multiple biological and psychological outcome measures. Subjective responses were quantified with a new rating scale, the HRS, which provided better resolution of dose effects than did the biological variables. A tolerance study then was performed, in which volunteers received four closely spaced hallucinogenic doses of DMT. Subjective responses demonstrated no tolerance, while biological measures were inconsistently reduced over the course of the sessions. Thus, DMT remains unique among classic hallucinogens in its inability to induce tolerance to its psychological effects. To assess the role of the 5-HT1A site in mediating DMT's effects, a pindolol pre-treatment study was performed. Pindolol significantly increased psychological responses to DMT, suggesting a buffering effect of 5-HT1A agonism on 5-HT2-mediated psychedelic effects. These data are opposite to those described in lower animal models of hallucinogens' mechanisms of action."
  130. Szara S.: "Dimethyltryptamine: Its Metabolism in Man; the Relation of its psychotic Effect to Serotonin Metabolism", Experientia, Bd. 12, S. 441-442, 1956.
  131. Szara S.: "The comparison of the Psychotic effect of tryptamine derivatives with the effects of mescaline and LSD-25 in self experiments", In: Garattini S., Ghetti V. (Hg.): "Psychotropic Drugs", Elsevier, S. 460-467, 1957.
  132. Szara S.: "Hallucinogenic effects and metabolism of tryptamine derivatives in man", Federation Proc., Bd. 20, S. 885- 888, 1961.
  133. Szara S.: "Correlation between metabolism and behavioral action of psychotropic tryptamine derivatives", Biochem. Pharmacol., Bd. 8, S. 32, 1961.
  134. Szara S.: "Effect of psychotropic tryptamine derivatives on the regional distribution of serotonin in the brain", In: Bradley P.B., Deniker P., Radouco-Thomas C. (Hg.): "Neuropsychopharmacology", Elsevier, 1959.·
  135. Szara S.: "Behavioral correlates of 6-hydroxylation and the effect of psychotropic tryptamine derivatives on brain serotonin levels", In: Richter (Hg.), S. 432-452.
  136. Szara S., Axelrod j.: "Hydroxylation and N- demethylation of N,N-dimethyltryptamine", Experientia, Bd. 15, S. 216-219, 1959.
  137. Szara S.,´Hearst E.: "The 6-hydroxylation of tryptamine derivatives: a way of producing psychoactive metabolites", Ann. N.Y. Acad. Sci., Bd. 96, S. 134-141, 1962.
  138. Szara S. et al.: "Metabolism of Hallucinogenic Tryptamine Derivatives. (intro. by J. Axelrod)", Clinical Neuropharmacology Research Center, NIMH. Abstract In: Federation Proc., Bd. 19, S. 23, 1960.
  139. Szara S., Hearst E., Putney F.: "Metabolism and behavioral action of psychotropic tryptamine homologues", Int. J. Neuropharmacol., Bd. 1, S. 111-117, 1962.
  140. "Psychological effects and metabolism of N,N-dimethyltryptamine in man", Arch. Gen. Psychilztry, Bd. 15, S. 320-329, 1966.
  141. Taborsky R.G., Delvigs P., Page I.H.: "6- Hydroxylation: Effect on the psychotropic potency of tryptamines", Science, Bd. 153, S. 1018-1020, 1966.
  142. Tanimukai H. et al.: "Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients", Brit. J. Psychiat., Bd. 117, S. 421-430, 1970.
  143. Thompson A.C., Nicollier G.F., Pope D.F: "Indolealkylamines of Desmanthus illinoensis and Their Growth Inhibition Activity", J Agric. Food Chem., Bd. 35, S. 361-365, 1987.
  144. Turner W.T., Merlis S.: "Effect of Some Indolealkylamines on Man", A.M.A. Archives of Neurology and Psychiatry, Bd. 81, S. 121-129, Januar, 1959.
  145. Uyeno E.T.: "6-Hydroxylated N,N-dimethyltryptamines and hallucinogenic potency", Proc. Mrest. Pharmacol. Sec., Bd. 12, S. 118-123, 1969.
  146. Wahba S.K., Elkheir Y.M.: "Dimethyltryptamine from the leaves of certain Acacia species of northern Sudan", Lloydia, Bd. 38, S. 176-177, 1975.
  147. Wassel, G.M. et al.: "Alkaloids from the rhizomes of Phragmites australis Cav.", Scientia Pharmaceutica, Bd. 53, S. 169-170, 1985.
  148. Weidmann H., Cerletti A.: "Studies on psilocybin and related compounds", Helv. Physiol. Acta, Bd. 18, S. 174-182, 1960.
  149. Well G.M., Metzner R., Leary T. (Hg.): "The Psychedelic Reader (selected articles from Psychedelic Revino)", University Books, 1965.
  150. Wieland T., Motsel W.: "Uber das Vorkommen von Bufotenin im gelben Knollenblatterpilz", Liebig. Ann. Chem., Bd. 581, S. 10-16, 1953.
  151. Wyatt R., Saavedra T., Axelrod J.: "A dimethyltryptamine-forming enzyme in human blood", Am. I. Psychiatry, 130, S. 754-760, 1973.